UPCOMING SESSIONS in ET
Thu, Jul 2, 2026
5:00 – 6:00 AM Bangkok
Second line options for relapsed/refractory disease COH experience with venetoclax for AL Amyloidosis Michael Rosenzweig Click To Register
UPCOMING SESSIONS in ET
Thu, Jul 2, 2026 · 5:00 – 6:00 AM Bangkok
Second line options for relapsed/refractory disease COH experience with venetoclax for AL Amyloidosis
Michael Rosenzweig
Click To Register
View all sessions

Left atrioventricular coupling index in transthyretin amyloid cardiomyopathy: Association with mortality

Source
Sciencedirect

Abstract

Background

Left atrioventricular coupling index (LACI) has emerged as a powerful marker of cardiac remodeling across a variety of cardiac diseases, however its prognostic value in the setting of transthyretin amyloid cardiomyopathy (ATTR-CM) remains largely unexplored.

Methods

Patients with ATTR-CM who underwent prospective evaluation comprising full echocardiographic assessment between 2021 and 2025 were included. LACI was measured as the ratio between the left atrial (LA) and the left ventricular (LV) end-diastolic volumes. The population was stratified based on LACI terciles. The study endpoint was all-cause mortality.